775 844
Conflicts of interest:
The authors have nothing to disclose.
References
[1]
Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation ther- apy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015;16:787–94.
[2]
Sandler H, Hu C, Rosenthal S, et al.[1_TD$DIFF]
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33(Suppl):LBA5002.
[3]
Morris W, Tyldesley S, Pai H, et al.[2_TD$DIFF]
ASCENDE-RT: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol 2015; 33(7 Suppl):3.[4]
Qi R, Moul J. High-risk prostate cancer: role of radical prostatec- tomy and radiation therapy. Oncol Res Treat 2015;38:639–44.[5]
Ross A. Multigene testing in localized prostate cancer. J Natl Compr Cancer Netw 2016;14:659–62.
[6]
Rowe SP, et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 2016;19:223–30.
[7]
Kishan AU, Shaikh T, Wang P-C, et al. Clinical outcomes for patients with Gleason score 9-10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis. Eur Urol 2017;71:766–73.
[8]
Harbin AC, Eun DD. The role of extended pelvic lymphadenectomy with radical prostatectomy for high-risk prostate cancer. Urol Oncol 2015;33:208–16.
[9]
Shipley W, Pugh S, Lukka H, et al.[3_TD$DIFF]
NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. J Clin Oncol 2016;34(2 Suppl):3.[10]
Taplin M-E, Montgomery B, Logothetis CJ, et al. Intense androgen- deprivation therapy with abiraterone acetate plus leuprolide ace- tate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32: 3705–15.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 7 4 – 7 7 5
775